Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
RAPP Stock Chart & Stats
$34.17
-$0.34(-1.94%)
At close: 4:00 PM EST
$34.17
-$0.34(-1.94%)
Day’s Range― - ―
52-Week Range$7.73 - $42.27
Previous CloseN/A
Volume10.11K
Average Volume (3M)318.91K
Market Cap
$1.63B
Enterprise Value$1.21B
Total Cash (Recent Filing)$490.54M
Total Debt (Recent Filing)$11.48M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
May 07, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding47,792,942
10 Day Avg. Volume238,581
30 Day Avg. Volume318,907
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-16.18
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.55K
Enterprise Value/Ebitda-9.96
Forecast
1Y Price Target
$49.80Price Target Upside45.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.36
Revenue Forecast (FY)$12.50M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAdvancement into Phase III registrational trials, supported by strong Phase II signals and a settled trial design, enhances prospects for pivotal data that could lead to regulatory approval and commercial uptake.
Product FormulationDevelopment of a long-acting injectable formulation aims to improve patient adherence, reduce breakthrough seizures, and broaden the drug's addressable market compared with oral therapies.
Strategic PartnershipExclusive Greater China licensing agreement with upfront payment, milestone potential, and tiered royalties provides non-dilutive funding and accelerates regional development and commercialization plans.
Bears Say
Analyst IndependenceBusiness relationships between the covering research firm and covered companies create potential conflicts that may bias analyst reports and weaken perceived objectivity.
Investor ConfidencePerceived conflicts of interest in research coverage could erode investor confidence in published recommendations and raise volatility around stock reactions to news.
Reputational RiskOngoing commercial ties between analysts and corporate clients may undermine the credibility of published research and complicate fundraising or partnership discussions for the company.
Rapport Therapeutics, Inc. News
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $7.73 and its highest was $42.27 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $1.63B.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 23 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Mar 10, 2026. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.677 by -$0.043.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -0.62.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 47,792,942 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.677. Following the earnings report the stock price went down -2.98%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapport Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.80 (45.74% Upside)
$49.80 (45.74% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 270.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $58.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
295.94%
12-Months-Change
Fundamentals
Return on Equity
-28.85%
Trailing 12-Months
Asset Growth
62.71%
Trailing 12-Months
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
RAPP Stock 12 Month Forecast
Average Price Target
$49.80
▲(45.74% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---